PAR 2.04% 24.0¢ paradigm biopharmaceuticals limited..

Ann: 2021 Annual Report and Appendix 4E, page-26

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 9,965 Posts.
    lightbulb Created with Sketch. 1296
    I seemed to have sparked a raw nerve with some contributors on this thread. Not sure which of my observations have triggered such a response or why it's actually warranted. My view remains positive long term but that doesn't preclude me wanting to see the Audit and Risk Committee do their job properly via (1) requesting PR set a date or milestone to bring in a independent Chair and (2) articulate KPI hurdles for awarding script. Insto investors (of which I'm one in my day to day) are increasingly playing an activist role particularly when the identify weak corporate governance. This is the point I'm trying to make above. My feel here is that PR is struggling to let go of the reins until he has at least delivered on a major milestone.

    In terms of my position disclosure - BUY - the current share price isn't driving my behaviour, rather I'm taking advantage of it at present as I feel the current narrative driving the price (further delays, incorrect IND submission assumptions etc) will turn positive into a non-stop feedback loop once IND is finally given the green light.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
-0.005(2.04%)
Mkt cap ! $83.98M
Open High Low Value Volume
25.0¢ 25.5¢ 24.0¢ $202.2K 814.1K

Buyers (Bids)

No. Vol. Price($)
5 181098 24.0¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 118621 5
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.